Bemnifosbuvir sulfate
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Bemnifosbuvir sulfate
- Molecular weight
- 1,261.16
- Structure (SMILES)
- CNc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)Oc2ccccc2)[C@@H](O)[C@@]1(C)F.CNc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)Oc2ccccc2)[C@@H](O)[C@@]1(C)F.O=S(=O)(O)O
- at 511 hemisulfate salt
- at 527
- At 527
- at 527 550 mg cyclosporine
- at 527 digoxin
- at 527 fed
- at 527 r07496998
- AT-511-hemisulfate salt
- At-527
- AT-527
- AT-527 (R07496998)
- AT-527 fed
- at527
- AT527
- bemnifosbuvir hemisulfate
- Bemnifosbuvir hemisulfate
- bemnifosbuvir sulfate
- Bemnifosbuvir sulfate
- BEMNIFOSBUVIR SULFATE [USAN]
- bemnifosbuvir sulfate usan
- ro7496998
- RO7496998
- CAS registry numbers
- 2241337-84-6
- ChEMBL ID
- CHEMBL5095037
- InChIKey
- QIGYBLSWYRTXCA-ZTVMIBNESA-N
- FDA ingredient codes (UNII)
- DAI4WL7JQ6
- 155926085
- 163192104
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -fos-; -vir
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005231
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT03219957
- NCT04019717
- NCT04309734
- NCT04396106
- NCT04709835
- NCT04889040
- NCT05126576
- NCT05618314
- Hydrogen bond acceptors
- 13
- Hydrogen bond donors
- 4
- Polar surface area
- 184.97
- Calculated partition coefficient (ALogP)
- 2.57
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 85
- Molecular formula
- C48H68F2N14O18P2S
- Monoisotopic mass
- 1260.40000287
- Natural product
- No
Related records
Trials (17)
- Bronchopulmonary PK of AT-527 (R07496998)
- Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)
- Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)
- Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
- Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
- Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
- Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
- Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
- Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
- Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
- Study of AT-527 in Healthy and HCV-Infected Subjects
- Study of AT-527 in Healthy Subjects (R07496998)
- Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
- Study of AT-527 in Subjects With Normal and Impaired Renal Function
- Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
- Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
- Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
In development for (4)
- Chronic hepatitis C virus infection Phase 2
- COVID-19 Phase 3
- Hepatitis C virus infection Phase 1
- Kidney disorder Phase 1